Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.49 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.49 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125978 | 1.00 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL6626310 | 1.00 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL2726068 | 1.00 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL5317301 | 0.98 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12356593 | 0.84 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13761212 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12141565 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL744840 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12356596 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL18049548 | 0.82 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-20240034733-A1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220389033-A1 | HETERO-BICYCLIC INHIBITORS OF KRAS | INCYTE CORPORATION | 2022-12-08 | — | — | US | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022068921-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2021105481-A1 | NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034733-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CHRNB2 4853/4885CHRNA4 4878/4885CHRNA3 4871/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CHRNB2 4683/4885CHRNA4 4853/4885CHRNA3 4842/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CHRNB2 4683/4885CHRNA4 4853/4885CHRNA3 4842/4885 |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | CHRNB2 870/4885CHRNA4 1000/4885CHRNA3 1043/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | CHRNB2 4568/4885CHRNA4 4673/4885CHRNA3 4559/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CHRNB2 4683/4885CHRNA4 4853/4885CHRNA3 4842/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CHRNB2 4683/4885CHRNA4 4853/4885CHRNA3 4842/4885 |
| US-20220389033-A1 | HETERO-BICYCLIC INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CHRNB2 4681/4885CHRNA4 4864/4885CHRNA3 4800/4885 |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | CHRNB2 3677/4885CHRNA4 3008/4885CHRNA3 2474/4885 |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | CHRNB2 629/4885CHRNA4 768/4885CHRNA3 908/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CHRNB2 4683/4885CHRNA4 4853/4885CHRNA3 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.